Skip to main content
Top
Published in: Modern Rheumatology 2/2013

01-03-2013 | Original Article

Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients

Authors: Arifumi Iwata, Kei Ikeda, Koichi Hirose, Hiroaki Takatori, Kentaro Takahashi, Yoshie Sanayama, Shigeru Tanaka, Akira Suto, Hiroshi Nakajima

Published in: Modern Rheumatology | Issue 2/2013

Login to get access

Abstract

Background

A significant proportion of patients with connective tissue disease (CTD) have gastric esophageal reflux disease (GERD) symptoms despite receiving proton pump inhibitors (PPIs). Although pre-meal administration of PPIs is recommended in Western countries, the benefit of this administration timing in Japanese CTD patients with refractory GERD symptoms has not been proven.

Objective

To determine whether pre-dinner administration of PPIs is more efficacious for refractory GERD symptoms in Japanese CTD patients.

Methods

CTD patients receiving oral PPIs were instructed to take PPIs 1 h before dinner. Gastrointestinal symptoms were evaluated with frequency scale for the symptoms of GERD (FSSG) and gastrointestinal symptom rating scale (GSRS) before and after the intervention.

Results

Pre-dinner administration of PPIs significantly improved FSSG total score, from a median of 8 to 6.5 (P = 0.005). Pre-dinner administration was more effective in patients with overt GERD symptoms (from median 18 to 10, P < 0.001) than in those with mild GERD symptoms (from median 2 to 2, P = 0.201). In addition to reflux syndrome, pre-dinner administration of PPIs significantly decreased abdominal pain syndrome and constipation syndrome of GSRS.

Conclusion

Pre-dinner administration of PPIs may increase their efficacy in Japanese CTD patients with GERD, especially those with overt symptoms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Ling TC, Johnston BT. Esophageal investigations in connective tissue disease which tests are most appropriate? J Clin Gastroenterol. 2001;32:33–6.PubMedCrossRef Ling TC, Johnston BT. Esophageal investigations in connective tissue disease which tests are most appropriate? J Clin Gastroenterol. 2001;32:33–6.PubMedCrossRef
2.
go back to reference Patti MG, Gasper WJ, Fisichella PM, Nipomnick I, Palazzo F. Gastroesophageal reflux disease and connective tissue disorders: pathophysiology and implications for treatment. J Gastrointest Surg. 2008;12:1900–6.PubMedCrossRef Patti MG, Gasper WJ, Fisichella PM, Nipomnick I, Palazzo F. Gastroesophageal reflux disease and connective tissue disorders: pathophysiology and implications for treatment. J Gastrointest Surg. 2008;12:1900–6.PubMedCrossRef
3.
go back to reference Daruwala C, Mercogliano G, Harder TP. Gastrointestinal manifestations of systemic lupus erythematosus and scleroderma. Clin Med Insights Gastroenterol. 2009;2:7–12. Daruwala C, Mercogliano G, Harder TP. Gastrointestinal manifestations of systemic lupus erythematosus and scleroderma. Clin Med Insights Gastroenterol. 2009;2:7–12.
4.
go back to reference Chong VH, Wang CL. Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singapore Med J. 2008;48:419–24. Chong VH, Wang CL. Higher prevalence of gastrointestinal symptoms among patients with rheumatic disorders. Singapore Med J. 2008;48:419–24.
5.
go back to reference Ebert EC. The gastrointestinal complications of myositis. Aliment Pharmacol Ther. 2010;31:359–65.PubMedCrossRef Ebert EC. The gastrointestinal complications of myositis. Aliment Pharmacol Ther. 2010;31:359–65.PubMedCrossRef
6.
go back to reference Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.PubMedCrossRef Domsic R, Fasanella K, Bielefeldt K. Gastrointestinal manifestations of systemic sclerosis. Dig Dis Sci. 2008;53:1163–74.PubMedCrossRef
7.
go back to reference Volter F, Fain O, Mathieu E, Thomas M. Esophageal function and Sjögren’s syndrome. Dig Dis Sci. 2004;49:248–53.PubMedCrossRef Volter F, Fain O, Mathieu E, Thomas M. Esophageal function and Sjögren’s syndrome. Dig Dis Sci. 2004;49:248–53.PubMedCrossRef
8.
go back to reference Marshall JB, Kretschmar JM, Gerhardt DC, Winship DH, Winn D, Treadwell EL, et al. Gastrointestinal manifestations of mixed connective tissue disease. Gastroenterology. 1990;98:1232–8.PubMed Marshall JB, Kretschmar JM, Gerhardt DC, Winship DH, Winn D, Treadwell EL, et al. Gastrointestinal manifestations of mixed connective tissue disease. Gastroenterology. 1990;98:1232–8.PubMed
9.
go back to reference Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.PubMedCrossRef Fujiwara Y, Arakawa T. Epidemiology and clinical characteristics of GERD in the Japanese population. J Gastroenterol. 2009;44:518–34.PubMedCrossRef
10.
go back to reference Hatlebakk JG, Katz PO, Camacho-Lobato L, Catell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–72.PubMedCrossRef Hatlebakk JG, Katz PO, Camacho-Lobato L, Catell DO. Proton pump inhibitors: better acid suppression when taken before a meal than without a meal. Aliment Pharmacol Ther. 2000;14:1267–72.PubMedCrossRef
11.
go back to reference Morise K, Iizuka A, Inagaki T, Sugie M, Matsunaga Y, Nakata K, et al. Clinical effect of omeprazole, a gastric proton pump inhibitor—comparative study on morning dose and bed-time dose in the treatment of peptic ulcer. Yakuri to Rinsyo. 1988;16:593–608. Morise K, Iizuka A, Inagaki T, Sugie M, Matsunaga Y, Nakata K, et al. Clinical effect of omeprazole, a gastric proton pump inhibitor—comparative study on morning dose and bed-time dose in the treatment of peptic ulcer. Yakuri to Rinsyo. 1988;16:593–608.
12.
go back to reference Shinomura K, Kaneyama S, Miyazaki Y, Okuda S, Iiishi H, Himeno S, et al. Mod Phys. 1994;14:69–84. Shinomura K, Kaneyama S, Miyazaki Y, Okuda S, Iiishi H, Himeno S, et al. Mod Phys. 1994;14:69–84.
13.
go back to reference Tateno M, Nakamura M. Phase I study of lansoprazole (AG-1749) antiulcer agent—capsule form—. Rinsyo Iyaku. 1991;7:51–62. Tateno M, Nakamura M. Phase I study of lansoprazole (AG-1749) antiulcer agent—capsule form—. Rinsyo Iyaku. 1991;7:51–62.
14.
go back to reference Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32:466–73.PubMed Yasuda S, Ohnishi A, Ogawa T, Tomono Y, Hasegawa J, Nakai H, et al. Pharmacokinetic properties of E3810, a new proton pump inhibitor, in healthy male volunteers. Int J Clin Pharmacol Ther. 1994;32:466–73.PubMed
15.
go back to reference Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.PubMedCrossRef Kusano M, Shimoyama Y, Sugimoto S, Kawamura O, Maeda M, Minashi K, et al. Development and evaluation of FSSG: frequency scale for the symptoms of GERD. J Gastroenterol. 2004;39:888–91.PubMedCrossRef
16.
go back to reference Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–52.PubMedCrossRef Dimenas E, Glise H, Hallerback B, Hernqvist H, Svedlund J, Wiklund I. Well-being and gastrointestinal symptoms among patients referred to endoscopy owing to suspected duodenal ulcer. Scand J Gastroenterol. 1995;30:1046–52.PubMedCrossRef
17.
go back to reference Kinoshita Y, Ishihara S. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia. Therap Adv Gastroenterol. 2008;1:191–9.PubMedCrossRef Kinoshita Y, Ishihara S. Causes of, and therapeutic approaches for, proton pump inhibitor-resistant gastroesophageal reflux disease in Asia. Therap Adv Gastroenterol. 2008;1:191–9.PubMedCrossRef
18.
go back to reference Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.PubMedCrossRef Fass R, Sifrim D. Management of heartburn not responding to proton pump inhibitors. Gut. 2009;58:295–309.PubMedCrossRef
19.
go back to reference Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way cross over study. Aliment Pharmacol Ther. 2006;24:1445–51.PubMedCrossRef Miki M, Adachi K, Azumi T, Koshino K, Furuta K, Kinoshita Y. A comparative study of intragastric acidity during post-breakfast and pre-dinner administration of low-dose proton pump inhibitors: a randomized three-way cross over study. Aliment Pharmacol Ther. 2006;24:1445–51.PubMedCrossRef
20.
go back to reference Xie HG, Stein CM, Kim RB, Wilikinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9:539–49.PubMedCrossRef Xie HG, Stein CM, Kim RB, Wilikinson GR, Flockhart DA, Wood AJ. Allelic, genotypic and phenotypic distributions of S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics. 1999;9:539–49.PubMedCrossRef
21.
go back to reference Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–8.PubMedCrossRef Furuta T, Shirai N, Kodaira M, Sugimoto M, Nogaki A, Kuriyama S, et al. Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori. Clin Pharmacol Ther. 2007;81:521–8.PubMedCrossRef
Metadata
Title
Pre-dinner administration increases the efficacy of proton pump inhibitors on refractory GERD symptoms in connective tissue disease patients
Authors
Arifumi Iwata
Kei Ikeda
Koichi Hirose
Hiroaki Takatori
Kentaro Takahashi
Yoshie Sanayama
Shigeru Tanaka
Akira Suto
Hiroshi Nakajima
Publication date
01-03-2013
Publisher
Springer Japan
Published in
Modern Rheumatology / Issue 2/2013
Print ISSN: 1439-7595
Electronic ISSN: 1439-7609
DOI
https://doi.org/10.1007/s10165-012-0662-5

Other articles of this Issue 2/2013

Modern Rheumatology 2/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.